Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Pfizer

This Dividend Stock Has Plunged Ahead of Trump’s Inauguration. Here Are 3 Reasons Investors Should Still Buy It.

For savvy investors, Pfizer could be an undervalued stock to buy here.

Barchart

'Pfizer Boob Job': Several UK Women Say Their Breasts 'Quadrupled In Size' After COVID Shots

UK women report significant breast enlargement after Pfizer COVID-19 vaccine. Possible link to rare condition PASH, but requires further research.

International Business Times UK

What to Expect From Pfizer's Next Quarterly Earnings Report

Pfizer is poised to announce its fourth-quarter results next month, and analysts predict a significant growth in the company’s bottom-line figure.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Unstoppable Yields: 3 Blue-Chip Stocks to Maximize Returns

Explore established industry leaders with impressive dividend yields that are demonstrating the potential for growth and continued performance in 2025.

MarketBeat

Teen's Breast Grew To Triple G-Cup Size After COVID Vaccinations: Researchers Call It 'Exceedingly Rare'

Researchers have identified the condition as Pseudoangiomatous stromal hyperplasia (PASH)-associated gigantomastia, an "exceedingly rare" condition linked to COVID-19 vaccination.

Medical Daily

Pfizer has increased prices on over 60 drugs in the U.S. as of Jan. 1

The U.S. continues to charge significantly higher prices for prescription drugs compared with similarly wealthy countries.

Fortune

Top 3 Stocks Seeing a Spike in Call Option Volume

Three stocks reported unusual call option volume this month, and the reasons why would make sense to all investors and Wall Street analysts.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Pfizer: 4 Reasons to Buy This Stock

Pharmaceutical giant Pfizer Inc. (NYSE: PFE) stock is trading back down near its pandemic lows. Every time it attempts to climb over the $30 mark, something ca

MarketBeat

Judge in Luigi Mangione Case Married to Ex-Pfizer Executive, Owns Thousands in Healthcare Stock: Report

The judge presiding over pre-trial hearings for Luigi Mangione has come under scrutiny for her financial and familial ties to the healthcare industry.

Latin Times

Love Dividends? 2 Passive Income Stocks to Scoop Up Now.

These consistent dividend-paying stocks could be a good addition to your portfolio.

Barchart

‘Heartless’ multinationals exploiting pensions loophole for UK workers

Hewlett Packard, American Express and Pfizer among firms to have frozen increases in payouts despite inflation

The Guardian - UK

Stock Index Futures Gain With All Eyes on Fed Rate Decision

December S&P 500 E-Mini futures (ESZ24) are up +0.22%, and December Nasdaq 100 E-Mini futures (NQZ24) are up +0.26% this morning as investors looked ahead to the Federal Reserve’s final policy decision of the year.

Barchart

Stocks Decline Ahead of Wednesday’s FOMC Meeting Results

The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -0.39%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.61%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.43%. Dec E-mini S&P futures (ESZ24 ) are down -0.48%, and Dec E-mini Nasdaq futures...

Barchart

Stocks Fall on Weakness in Chip Makers and Healthcare Companies

The S&P 500 Index ($SPX ) (SPY ) today is down -0.49%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.67%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.51%. Dec E-mini S&P futures (ESZ24 ) are down -0.51%, and Dec E-mini Nasdaq futures...

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

More ‘discreet’ Viagra-type drug could soon be available in Britain

US company Viatris has applied for a UK trademark for wafer-like film that dissolves in the mouth

Creative Bloq

"I’d love to see fewer boundaries in the design industry”: a day in the life of Amy Globus

Team's co-founder discusses approaching design with an artist's sensibility.

Top News

President-Elect Trump Hosts Pharmaceutical Ceos For Dinner At Mar-A-Lago

President-elect Trump's dinner with pharmaceutical executives and healthcare appointees highlights industry collaboration and healthcare challenges.

Barchart

Pfizer Stock: Is PFE Underperforming the Healthcare Sector?

Despite Pfizer's underperformance relative to the healthcare sector, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Pfizer's New Chief Scientific Officer Charts R&D Vision For High And Low-Risk Investments

Pfizer's Chris Boshoff outlines plans to prioritize high-return projects, with a focus on obesity, Oncology, and oral GLP-1 therapies, amid Q3 growth.

MarketBeat

Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch

Here's why Eli Lilly, Pfizer, and AstraZeneca are biotech stocks worth considering, with strong pipelines and growth potential beyond vaccines.

MarketBeat

Is Biotech’s Bull Run Over? Examining Election Impacts

The biotech sector's breakout attempt post-election reversed sharply, with ETFs like IBB and XBI falling and invalidating the long-term bullish setup.

International Business Times

Pfizer Not Eligible To Recover $75 Million From Settlement With SEC

Judge ruled that Pfizer could not recover $75 million left over from insider trading SEC settlement.

The Conversation

The latest COVID booster will soon be available. Should I get one? Am I eligible?

Australia’s Therapeutic Goods Administration (TGA) has recently approved a new COVID booster. The shot was developed by Pfizer and targets the JN.1 sub-variant of Omicron.

MarketBeat

ORIC: Working with Two Pharma Giants, Analysts See +100% Upside

ORIC Pharmaceuticals is a stock analyst price targets currently signal double-bagger potential in. See what the excitement around this firm is all about.

Barchart

Thursday's Unusual Options Activity Reveals 3 Promising Long-Term Investments

Thursday's trading session revealed 33 call options with unusually high activity and boasting expiration dates of 365 days or more. Three have emerged as promising long-term investments from this diverse pool of potential opportunities.

1 … 11 12 13 14

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.